BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to speed up healing in many tissues: tendons, the gut lining, muscle, and nerve ^[5][6]. The most consistent explanation researchers give is that it helps the body grow new blood vessels into an injury, which brings the oxygen and nutrients repair needs ^[4].

Here is the honest part. Almost all of this evidence is in animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous human trials ^[2]. BPC-157 is not an approved drug anywhere, it is banned in sport, and popular claims about weight loss or muscle building are not supported by the published science ^[2]. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" simply means a peptide of fifteen amino acids, and "stable gastric" because the sequence comes from a cytoprotective (cell-protecting) protein in gastric juice and resists breakdown in the stomach. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it is also catalogued under research designations such as PL 14736, PLD-116, and PL-10. It is a synthetic research peptide, not a natural product you can extract, and not an approved drug.

How it works

The best-characterized mechanism is angiogenesis — the formation of new blood vessels. In a 2017 study spanning a chick-membrane model, rat hindlimb ischemia, and human endothelial (blood-vessel-lining) cells, BPC-157 increased the expression of a key vessel-growth receptor called VEGFR2 and promoted its internalization, switching on the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect ^[4]. In plain terms: it seems to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model ^[4].

Beyond vessels, the peptide is described as a brain-gut-axis mediator that modulates serotonin and dopamine systems and engages cell-migration pathways such as FAK-paxillin, along with Egr-1/NAB2 and JAK-2 signaling ^[7]. Reported routes also include sensitizing the growth-hormone receptor in tendon cells. The throughline is a peptide that nudges several repair-related signals at once rather than hitting a single target.

What the research shows

Foundational cytoprotection. The compound's name traces to its gut origins. In Wistar rats, BPC-157 reduced gastric-ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric, and ulcer-formation inhibition ratios of roughly 46-66% at higher doses ^[5].

Tendon. In a fully transected rat Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures and stimulated tendon-cell (tendocyte) outgrowth in culture, with better collagen organization and restored tendon integrity versus untreated controls ^[6].

Pharmacokinetics. The first formal PK/ADME work, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism ^[3]. A short half-life means the intact peptide does not linger in the bloodstream.

Human evidence. It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers — but the sample was two people, and it was a safety pilot, not an efficacy trial ^[1]. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational ^[2].

Reported effects, cautions & safety

The safety picture inside the tiny human dataset and the animal work is reassuring as far as it goes, but "as far as it goes" is the operative phrase: the absence of long-term, large-sample human safety data means the real-world safety profile is genuinely unknown ^[2].

Several cautions follow directly from the literature:

• Evidence is overwhelmingly preclinical. Most of what is reported comes from rodents, and a large share of the foundational work originates from a single research group, which newer authors explicitly flag as raising independent-replication questions ^[2].
• Unregulated supply. BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, so product identity, purity and dose are unverified outside formal studies.
• Banned in sport. It is prohibited at all times by the World Anti-Doping Agency under the S0 (non-approved substances) category — a direct concern for any competitive athlete.
• Skeptical claims. Common online claims such as weight loss, muscle building, or raising testosterone are not supported by the published evidence and should be treated skeptically.

There are no community-anecdote reports compiled in this desk's source material for BPC-157, so none are presented here; the cautions above are drawn from the cited literature, not from user testimony.

Where it fits in recovery research

Among the four peptides on this desk, BPC-157 is the lead and the most broadly studied — but breadth is not the same as depth. Its animal record spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward story, while its human file remains three small pilots ^[2]. Read alongside TB-500, which approaches repair through cell migration, and GHK-Cu, which carries the strongest human (topical) data, BPC-157 illustrates the central tension of this whole field: a coherent, decades-deep preclinical signal that has barely crossed into controlled human work. See the comparison page for how it lines up against the others.